Hydroxychloroquine in lupus erythematosus, a new horizon of the old drug

Furukawa, Fukumi

doi:10.24294/ti.v1.i3.127

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various treatments are known in AT and alopecia universalis (AU), and although however certain treatments have shown significant hair regrowth, no treatment is completely effective [4] . Recently, the efficacy of hydroxychloroquine [5,6] in the treatment of AT has been reported [7] but its use for extensive alopecia areata is still controversial [8] . Tofatinib is also reported to show efficacy in severe AA including AT and AU [9] .…”

Section: Discussionmentioning

confidence: 99%

Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis

Yoshimasu

Mikita²,

Ikeda³

et al. 2018

Trends Immunother

Self Cite

View full text Add to dashboard Cite

Alopecia totalis (AT) with body hair loss is the most severe type of alopecia areata (AA). The ability to develop hair is suggested to be poor in such severe AA, because AT does not respond to corticosteroid pulses and immunotherapy using squaric acid dibutylester (SADBE) or diphenylcyclopropenone (DPCP). The purpose of this study is to assess the possibility of hair regrowth in AT with body hair loss. Ten patients with AT who did not respond to topical immunotherapies, received triamcinolone acetonide (TA) injections. Undiluted or 2-fold diluted solutions of TA were prepared and 0.1–0.2 mL of either of the two solutions was administered to each patient. In total, 2 mL of the selected solution was injected monthly into each area. In cases where vellus hair developed after the injections, we restarted the immunotherapy using SADBE or DPCP and continued the therapies for more than half a year. The development of vellus hair after TA injections was defined as a good response. Complete response rate to the topical injection of TA was 10% (1/10), however the partially good response rate was 60% (6/10). The good responders showed the anagen stage of hair follicle after TA injections. Furthermore, the complete responder to TA showed susceptibility to the subsequent immunotherapy and more regrowth of hair was seen. Even if patients with AT have suffered for a prolonged period since onset, it is possible to recover the hair cycle if they show susceptibility to intralesional corticosteroid and subsequent immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis

Yoshimasu

Mikita²,

Ikeda³

et al. 2018

Trends Immunother

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, our recent experiments of mast cells suggested that mast cells are biphasic-reaction in the skin lesions [7,8] . The HCQ effects on mast cell biology will be expected for better treatment of CLE [9] . …”

Section: Discussionmentioning

confidence: 99%

Hydroxychloroquine enhanced urticarial reaction in a patient with discoid lupus erythematosus

et al. 2017

Self Cite

View full text Add to dashboard Cite

Discoid lupus erythematosus (DLE) is an autoimmune disorder that usually occurs on sun exposed areas. We describe a case of a 31-year-old man with reddish-purple, atrophic plaques on the nose and the bilateral cheeks. Histopathologic and direct immuneofluorescent studies confirmed DLE diagnosis. The skin lesion had been previously resistant to topical clobetasol propionate 0.05% and tacrolimus 0.1% since 2012, and were treated with oral hydroxychloroquine (HCQ) (300 mg daily). Two weeks later, the diarrhea happened frequently as side effects. Then, the decreased HCQ 200 mg daily improved the diarrhea moderately. The patient who had a history of urticaria also complained about urticarial reaction much more frequently 3 weeks later more than the start, which was improved very much by epinastine (10 mg daily) administration. Cutaneous lupus erythematsus disease area and severity index (CLASI) activity score improved from 11 to 5 for 3 months.

show abstract

“…HCQ is an old and new drug. It has a long history of use, and it is only recently that one of its mechanisms has been clarified from the perspective of immunity [23] . This drug has a wide range of ac-tions such as anti-inflammatory action, immunomodulatory action, antimalarial action, and antitumor action.…”

Section: Action Mechanisms Of Hydroxychloroquinementioning

confidence: 99%

Hydroxychloroquine for the treatment of cutaneous lupus erythematosus

Furukawa

2021

Trends Immunother

Self Cite

View full text Add to dashboard Cite

In recent years of immunology, the understanding of innate immunity has deepened, and the concept of innate immunity has been proposed even in the area of acquired immune subjects. The conventional immunosuppressive treatments have mainly controlled the step of acquired immunity. However, the involvement of innate immunity was clarified for hydroxychloroquine (HCQ), which has been confirmed to be very effective for cutaneous lupus erythematosus (CLE). This review introduces the mechanism of development of CLE from the viewpoint of autoantibodies, cytokines, and innate immunity. Furthermore, the mechanism of HCQ is introduced and discussed.

show abstract

Hydroxychloroquine in lupus erythematosus, a new horizon of the old drug

Abstract: CITATIONFurukawa F. Hydroxychloroquine in lupus erythematosus, a new horizon of the old drug. Trends Immunother 2017; 1(3): 99-100.

Cited by 3 publications

References 10 publications

Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis

Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis

Hydroxychloroquine enhanced urticarial reaction in a patient with discoid lupus erythematosus

Hydroxychloroquine for the treatment of cutaneous lupus erythematosus

Contact Info

Product

Resources

About